Insight Molecular Diagnostics Inc.
IMDX
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $129.5M
$3.86
▼ -3.74%
P/E
-2.26
Mkt Cap
$129.5M
52-Wk Range
$2.40–$8.51
52-Week Range
$2.40 - $8.51
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 56.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary gene expression technology platform
- Strategic partnership with Life Technologies for Oncomine assay development
- Clinical validation data supporting early cancer detection
- Integrated laboratory-developed test (LDT) capabilities
Bear Case
1 risk
- Above-average volatility (beta 1.8).
Growth
Revenue decline expected
Increasing adoption of precision oncology and early cancer screening
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-33.5% over 3m
Quality
Thin
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying IMDX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 10, 2026
Reported EPS of -$0.23 vs -$0.25 consensus (+9.4% surprise). Revenue of $239.0K vs $437.5K expected (-45.4%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+9.4%
Revenue trend · last 8Q
—
—
—
—
+398%
+126%
-23%
-54%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q2 26
$104.0K
$115.0K
$1.5M
$2.1M
$518.0K
$260.0K
$1.1M
$239.0K
Margins · last 8Q
Gross
65.7%
Profit
-4711.3%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How IMDX stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related